#文章仅代表作者观点,不代表IPRdaily立场#
原标题:美国司法部、专利商标局和国家标准与技术研究院宣布关于标准必要专利救济的联合政策声明
2019年12月19日,美国司法部(Department of Justice,“DOJ”)、专利和商标局(U.S. Patent and Trademark Office,“USPTO”)和国家标准与技术研究院(National Institute of Standards and Technology,“NIST”)发布了一份关于标准必要专利(standard-essential patents,“SEP”)救济的联合政策声明。该专利持有人已同意许可其专利以公平,合理和非歧视(F / RAND)的条款。本声明取代了司法部和美国专利商标局共同发布的2013年关于SEP补救措施的政策声明。
司法部反托拉斯部司法部长助理马坎·德莱希姆说:“根据美国宪法第1条第8条的规定,我们的专利制度奖励发明人在有限的时间内实践其发明的专有权。” “今天的《政策声明》认识到,如果许可谈判失败,则SEP持有人应可获得专利侵权的适当补救措施,包括禁令性救济。为了保持竞争和激励创新,以及继续参与标准制定活动,这将为美国消费者带来实质性利益,必须提供各种补救措施。”
为此,《声明》明确指出,专利所有人以F / RAND条款许可专利的承诺并不妨碍获得任何特定补救措施,包括禁令救济。这些机构明确指出,没有“特殊的法律规则集”适用于标准必要程序,法院,美国国际贸易委员会和其他决策者能够根据当前法律和相关事实评估适当的补救措施。根据该声明,“专利权人的特定F / RAND承诺,[标准开发组织的]知识产权政策以及专利权人与实施者之间的许可谈判的个别情况都可能与确定侵权行为的补救措施有关。标准必要的专利,具体取决于每种情况。”
该声明是在司法部退出2013年SEP政策声明后做出的,该声明被错误地解释为暗示适用于SEP的特殊救济措施以及寻求禁制令或排除令可能会损害竞争。
助理总检察长德拉希姆说:“我们的专利制度使美国经济成为世界的创新之都,我们不应滥用反托拉斯法来削弱创新的动力。”
自该公告发布以来,许多行业参与者和政策制定者在准备新声明时已向代理商提供了投入。
助理总检察长德拉希姆说:“随着各机构起草新的声明,我们重视整个行业和政策领域的意见,尤其是参议院知识产权委员会主席汤姆·提利斯和排名靠前的克里斯·库恩斯的意见。” “正如新声明所强调的,最终,对于标准必要专利没有特殊的补救措施。所有专利权人都有寻求禁令救济的法定权利,这份联合声明重申,如果这样做,代理机构将不会对他们不利。(翻译自谷歌)
以下为DOJ发布的新闻稿及联合政策声明全文。
Department of Justice, United States Patent and Trademark Office, and National Institute of Standards and Technology Announce Joint Policy Statement on Remedies for Standard-Essential Patents
Today the Justice Department, U.S. Patent and Trademark Office (USPTO), and National Institute of Standards and Technology (NIST) issued a joint policy Statement regarding the treatment of standard-essential patents (SEP) where the patent holder has agreed to license its patents on fair, reasonable, and non-discriminatory (F/RAND) terms. This Statement replaces the 2013 policy statement on SEP remedies issued jointly by the Department of Justice and USPTO.
“Consistent with Article I, Section 8 of the U.S. Constitution, our patent system rewards inventors with an exclusive right to practice their inventions for a limited time,” said Assistant Attorney General Makan Delrahim of the Justice Department’s Antitrust Division. “Today’s Policy Statement recognizes that when licensing negotiations fail, appropriate remedies for patent infringement, including injunctive relief, should be available to SEP holders. The availability of the full range of remedies is necessary in order to preserve competition and incentives for innovation, and for continued participation in standards-setting activities, which can produce substantial benefits for American consumers.”
To this end, the Statement clarifies that a patent owner’s promise to license a patent on F/RAND terms is not a bar to obtaining any particular remedy, including injunctive relief. The agencies make clear that no “special set of legal rules” apply to SEPs, and the courts, the U.S. International Trade Commission, and other decision makers are able to assess appropriate remedies based on current law and relevant facts. According to the Statement, “The particular F/RAND commitment made by a patent owner, the [standard development organization’s] intellectual property policies, and the individual circumstances of licensing negotiations between patent owners and implementers all may be relevant in determining remedies for infringing a standards-essential patent, depending on the circumstances of each case.”
The Statement follows the Justice Department’s withdrawal from the 2013 SEP policy statement, which had been construed incorrectly as suggesting that special remedies applied to SEPs and that seeking an injunction or exclusion order could potentially harm competition.
“Our patent system is what has made the American economy the innovation capital of the world, and we should not misapply the antitrust laws to diminish the incentive to innovate,” said Assistant Attorney General Delrahim.
Since that announcement, many industry participants and policymakers have provided input to the agencies as they prepared the new Statement.
“We value the input provided across the industry and policy spectrum as the agencies drafted a new Statement, in particular the input from Senate Intellectual Property Committee Chairman Thom Tillis and Ranking Member Chris Coons,” said Assistant Attorney General Delrahim. “As the new Statement emphasizes, ultimately, there is no special set of remedies for standard-essential patents. All patent owners have a statutory right to seek injunctive relief, and this joint statement reaffirms that if they do so the agencies will not put a thumb on the scale against them.”
来源:IPRdaily综合美国司法部网站
编辑:IPRdaily王颖 校对:IPRdaily纵横君
推荐阅读(点击图文,阅读全文)
广东省市场监管局印发《2020年粤港澳大湾区高价值专利培育布局大赛工作方案》
活动预告!中国医疗器械知识产权峰会将于2020年3月19-20日隆重举行!
生而不凡!2019年中国“40位40岁以下企业知识产权精英”榜单揭晓
“投稿”请投邮箱“iprdaily@163.com”
「关于IPRdaily」
IPRdaily成立于2014年,是全球影响力的知识产权媒体+产业服务平台,致力于连接全球知识产权人,用户汇聚了中国、美国、德国、俄罗斯、以色列、澳大利亚、新加坡、日本、韩国等15个国家和地区的高科技公司、成长型科技企业IP高管、研发人员、法务、政府机构、律所、事务所、科研院校等全球近100多万产业用户(国内70万+海外30万);同时拥有近百万条高质量的技术资源+专利资源,通过媒体构建全球知识产权资产信息第一入口。2016年获启赋资本领投和天使汇跟投的Pre-A轮融资。
(英文官网:iprdaily.com 中文官网:iprdaily.cn)
本文来自IPRdaily综合美国司法部网站并经IPRdaily.cn中文网编辑。转载此文章须经权利人同意,并附上出处与作者信息。文章不代表IPRdaily.cn立场,如若转载,请注明出处:“http://www.iprdaily.cn/”
文章不错,犒劳下辛苦的作者吧